Lyra Therapeutics, Inc.
LYRA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,534 | $1,558 | $1,363 | $285 |
| % Growth | -1.5% | 14.3% | 378.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $29,694 |
| Gross Profit | $1,534 | $1,558 | $1,363 | -$29,409 |
| % Margin | 100% | 100% | 100% | -10,318.9% |
| R&D Expenses | $43,766 | $48,029 | $38,797 | $29,694 |
| G&A Expenses | $18,501 | $19,057 | $17,556 | $14,206 |
| SG&A Expenses | $18,501 | $19,057 | $17,556 | $14,206 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $35,615 | $1,592 | $1,316 | -$29,694 |
| Operating Expenses | $97,882 | $68,678 | $57,669 | $14,206 |
| Operating Income | -$96,348 | -$67,120 | -$56,306 | -$43,615 |
| % Margin | -6,280.8% | -4,308.1% | -4,131% | -15,303.5% |
| Other Income/Exp. Net | $2,952 | $4,499 | $1,041 | $102 |
| Pre-Tax Income | -$93,396 | -$62,621 | -$55,265 | -$43,513 |
| Tax Expense | $39 | $59 | $13 | $0 |
| Net Income | -$93,435 | -$62,680 | -$55,278 | -$43,513 |
| % Margin | -6,090.9% | -4,023.1% | -4,055.6% | -15,267.7% |
| EPS | -1.43 | -1.26 | -1.83 | -3.35 |
| % Growth | -13.5% | 31.1% | 45.4% | – |
| EPS Diluted | -1.43 | -1.26 | -1.83 | -3.35 |
| Weighted Avg Shares Out | 65,114 | 49,746 | 30,236 | 12,986 |
| Weighted Avg Shares Out Dil | 65,114 | 49,804 | 30,236 | 12,986 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,952 | $4,499 | $1,041 | $102 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $471 | $278 | $1,067 | $1,001 |
| EBITDA | -$60,262 | -$65,250 | -$53,923 | -$42,614 |
| % Margin | -3,928.4% | -4,188.1% | -3,956.2% | -14,952.3% |